Caris Life Sciences stock has declined 29% in 2026, but developments related to ChromoSeq and Detect may potentially alter its trajectory. The stock's performance is being reported alongside that of other companies, with some experiencing significant gains or losses. It is unclear how the stock will perform going forward, with potential for change due to various factors.